RecruitingNCT06859515
A Long-term Follow up Study of EXG102-031 in Participants With wAMD
A Long-term Follow-up Study to Evaluate the Injection of EXG102-031 Ophthalmic Injection in Participants With Wet Age-related Macular Degeneration (wAMD).
Sponsor
Guangzhou Jiayin Biotech Ltd
Enrollment
42 participants
Start Date
Mar 13, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.
Eligibility
Min Age: 50 Years
Inclusion Criteria2
- Previously received treatment with EXG102-031 in the study (EXG102-031-111);
- Paticipantes are informed consent and willingness to follow protocol procedures.
Exclusion Criteria1
- \. Paticipantes are unwilling or unable to participate in long-term follow-up
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNo intervention, only for observational studies
No intervention, only for observational studies
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06859515
Related Trials
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636181 locations
MMP-9 Inhibition for Recalcitrant Wet AMD
NCT045041231 location
Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)
NCT069524524 locations
Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals
NCT068752451 location